Survodutidesafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Survodutide as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Survodutide is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Survodutide's safety profile in Phase II parallels the broader dual-agonist class: gastrointestinal predominance (nausea, vomiting, diarrhoea, constipation) that is dose-dependent and titration-responsive. The glucagon-receptor component has not produced significant hyperglycaemia in Phase II — consistent with retatrutide's Phase II experience and supporting the pharmacological argument that GLP-1-driven glucose lowering compensates for glucagon-driven hepatic glucose mobilisation at clinically relevant doses. A distinctive survodutide safety consideration is modest heart rate elevation, somewhat higher than seen with pure GLP-1R agonists — likely reflecting the glucagon-receptor component's chronotropic effects. Phase III monitoring includes cardiovascular safety endpoints. Hepatic effects are the direction of interest rather than concern — survodutide has demonstrated hepatic fat reduction and improved liver-function markers in MASLD/MASH populations. Transaminase elevations have been favourable direction rather than adverse. The FDA-mandated thyroid C-cell carcinoma class warning is expected to apply based on the class-wide rodent mechanism. Longer-term safety data on rare adverse events (acute pancreatitis, biliary disease, retinopathy) will emerge through the Phase III programme. The Phase II 46-week safety data are encouraging in the expected domains. Phase III will provide the larger and longer-duration dataset required for marketing authorisation.

UK regulatory status

Survodutide is **not** authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds **no marketing authorisation** in any jurisdiction as of 2026. The compound is in Phase III clinical development by Boehringer Ingelheim / Zealand Pharma through the SYNCHRONIZE and LIVERAGE programmes; first regulatory filings are anticipated 2026-2028. Access is restricted to Phase III clinical-trial participation at selected UK NHS and private clinical-trial sites. Supply outside the clinical-trial framework is not legally available through MHRA-regulated channels. As a Phase III dual-agonist with substantial commercial expectations, survodutide has some emerging research-chemical-market presence though less prominent than the more established semaglutide or the flagship-Phase-III retatrutide. Grey-market supply of clinical-development peptides carries substantial safety and regulatory risk pending licensing. Survodutide is not on the WADA Prohibited List; the GLP-1R and glucagon-R class are not currently prohibited. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, survodutide work in vertebrates requires standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Survodutide is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Survodutide research context including mechanism, study citations, and references, see the main Survodutide research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.